The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.

References

• Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989; 73:90–9
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Optimizing the use of erythropoietic agents – pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 (Suppl 5) 66–70
   PubMed Web of Science ®Google Scholar
• Xue JL, St Peter WL, Ebben JP, . Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40:1153–61
   PubMed Web of Science ®Google Scholar
• Hörl WH, Macdougall I, Rossert J, . Predialysis survey on anemia management: patient referral. Am J Kidney Dis 2003; 41:49–61
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Bárány P, . European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2) ii1–ii47
   PubMedGoogle Scholar
• National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 (Suppl 3) S11–S145
   PubMed Web of Science ®Google Scholar
• Jones M, Ibels L, Schenkel B, . Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004; 65:757–67
   PubMed Web of Science ®Google Scholar
• Gouva C, Nickolopoulos P, Ioannidis JPA, . Treating anaemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66:753–60
   PubMed Web of Science ®Google Scholar
• Dean BB, Dylan M, Gano Jr A, . Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005; 21:981–7
   PubMed Web of Science ®Google Scholar
• Lu WX, Jones-Burton C, Zhan M, . Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005; 101:79–86
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Robson R, Opatrna S, . Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1:1211–5
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Bailon P, Tare N, . CERA (continuous erythropoiesis receptor activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol 2003; 14:769A. [Abstract SU-PO1063]
   Web of Science ®Google Scholar
• Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007; 16:1649–61
   PubMed Web of Science ®Google Scholar
• Levin NW, Fishbane S, Valdés Cañedo F, . on behalf of the MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370:1415–21
   PubMed Web of Science ®Google Scholar
• Sulowicz W, Locatelli F, Ryckelynck J-P, . on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2:637–46
   PubMed Web of Science ®Google Scholar
• Chapel SH, Veng-Pedersen P, Schmidt RL, . Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 2001; 29:425–31
   PubMed Web of Science ®Google Scholar
• Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002; 69:265–74
   PubMed Web of Science ®Google Scholar
• Al-Huniti NH, Widness JA, Schmidt RL, . Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. J Pharmacol Exp Ther 2004; 310:202–8
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen P, Chapel S, Al-Huniti NH, . Pharmacokinetic tracer kinetic analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 2004; 25:149–56
   PubMed Web of Science ®Google Scholar
• Glaspy J, Henry D, Patel R, . Darbepoetin Alfa 20010162 Study Group. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005; 41:1140–9
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646–9
   PubMed Web of Science ®Google Scholar
• Skluzacek PA, Szewc RG, Nolan CR 3rd, . Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003; 42:1169–76
   PubMed Web of Science ®Google Scholar